• search
Fill Finish Development and Manufacturing Services Fill Finish Development and Manufacturing Services

Fill Finish Development and Manufacturing Services

Our fill finish capability caters to a wide range of recombinant protein therapeutics.

With over 10,000 Sq.m of fill finish footprint, we can support filling of a wide range of presentations – vials (liquid and lyophilized), pre-filled syringes and autoinjectors. 

Our automated fill finish facility efficiently handles high-accuracy, high-viscosity, low-volume protein filing. End-to-end single-use capability enables for faster change over and assurance of cleaning validation. 

Our integrated approach to quality management systems enables greater flexibility and leverage pan - organization experience in managing regulatory audits.

Speak to our experts

Fill Range and Presentation

Fill range is 0.1-100 ml, Vials: 2-100 ml, PFS and auto injector: 0.1-1 ml

Manufacturing Process Flexibility and Formulation

  • Manufacturing process flexibility: peristaltic, rotary piston, end-of-end single-use system, sterile filling
  • Formulation: liquid, lyophilized

Why Aurigene Pharmaceutical Services?

100+ successful regulatory audits

10+K Sq.m facility footprints

300+ tech operations professionals

Operations supported by digital infrastructure

Virtual Tour

 
“Bathtub Chemistry” - Necessity and Aspects of Process Research

MAY 19, 2023

“Bathtub Chemistry” - Necessity and Aspects of Process Research

Medicine is an essential part of our life. Since ancient time human civilization has been tirelessly engaged to understand the cause and effect of a disease. Sometimes they win and many times they lose. But the story of their curiosity and enthusiasm is a never damping process. On the contrary it increases day by day, year after year.Drug discovery is a vast and ...

Read More

Biologics Manufacturing Services

Our manufacturing services cater to both GMP and non-GMP manufacturing for pre-clinical development as well as GMP operation to support clinical or commercial needs for any recombinant proteins expressed in suspension mammalian culture or E. coli. ...

Read More

Development of quick quantification method for muscle injury recovery evaluation in thermal injury mice model

Challenges: The evaluation of Evans Blue Dye (EBD) by fluorescence measurements of cryosections of individual muscle sections, and its quantification by auto fluorescence is a laborious and time-consuming process. Study design: Both sham and thermal injury techniques were followed. The evaluation of EBD was done to assess the effectiveness of two compounds in the...

Read More

An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives

2016

A convenient and one-pot synthesis of tetracyclic isoindolo [1,2-a]quinazoline derivatives via Lewis acid mediated sequential C–N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazol...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack